+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P12110(RNF139 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P12110(RNF139 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The RNF139 antibody is a tool used to detect RNF139 (Ring Finger Protein 139), an E3 ubiquitin ligase belonging to the RNF family. RNF139. also known as TRC8. plays a critical role in the ubiquitin-proteasome system, regulating protein degradation and cellular processes such as endoplasmic reticulum-associated degradation (ERAD), cholesterol homeostasis, and DNA damage response. It contains a conserved RING domain essential for its enzymatic activity and a transmembrane domain anchoring it to the ER membrane. Dysregulation of RNF139 has been implicated in cancer, particularly renal cell carcinoma and hereditary leiomyomatosis, due to its role in degrading tumor suppressors like HIF-1α and modulating mTOR signaling.

Antibodies targeting RNF139 are widely utilized in research to study its expression, localization, and function. They enable techniques such as Western blotting, immunohistochemistry, and immunofluorescence to assess protein levels in tissues or cell lines. Specificity is validated via knockout controls or siRNA knockdown. Commercially available RNF139 antibodies are often developed in hosts like rabbits or mice, with applications in both basic and translational research. Studies using these antibodies have revealed RNF139's involvement in tumor progression, metabolic disorders, and stress responses, highlighting its potential as a therapeutic target or biomarker. Researchers rely on these tools to explore molecular mechanisms underlying diseases linked to ubiquitination pathways.